Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This review provides a comprehensive overview of recent advances in the management of acute coronary syndromes, emphasizing the role of timely reperfusion, bleeding avoidance strategies, and potent antiplatelet therapies.
Unstable coronary artery plaque is the most common underlying cause of acute coronary syndromes (ACS) and can manifest as unstable angina, non-ST segment elevation infarction (NSTE-ACS), and ST elevation myocardial infarction (STEMI), but can also manifest as sudden cardiac arrest due to ischaemia induced tachyarrhythmias. ACS mortality has decreased significantly over the last few years, especially from the more extreme manifestations of ACS, STEMI, and cardiac arrest. This trend is likely to continue based on recent therapeutic progress which includes novel antiplatelet agents such as prasugrel, ticagrelor, and cangrelor.
No takes yet. Share an insight, caveat, or question.
Meier et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: